icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm
16 Feb, 2021 20:26

Russian-made Sputnik V and EpiVacCorona vaccines are effective against UK variant of coronavirus – watchdog

Russian-made Sputnik V and EpiVacCorona vaccines are effective against UK variant of coronavirus – watchdog

Russia’s Sputnik V and EpiVacCorona vaccines have been proven to be effective against the UK variant of the coronavirus, a government agency has said.

Serum obtained from people who took the Sputnik V and EpiVacCorona vaccines and had antibodies to the novel coronavirus, demonstrated a “protective effect” against the UK variant, Russia’s consumer protection agency, Rospotrebnadzor, said in a statement to the media.

It added that the vaccines have shown to be just as good against the British strain as they are against the ordinary SARS-CoV-2 virus, which causes Covid-19.

The research was carried out by the Siberia-based Vector Institute, which developed EpiVacCorona. Russian President Vladimir Putin previously asked it to check whether the country’s vaccines are effective against the new strains of the virus. EpiVacCorona was cleared for mass production back in December, with the first batch of 45,000 doses released for sale to citizens in January.

Officials around the world are concerned that the emergence of new variants, which prompted additional restrictions in some countries, can potentially undermine the ongoing immunization campaigns.

Last August, Russia became the first country to register a Covid-19 vaccine – Sputnik V – with its national regulator. The vaccine, developed by the Moscow-based Gamaleya Institute, has since been authorized for emergency use in 26 countries, including Argentina, Serbia, Iran, Pakistan, Bahrain and the UAE.

Also on rt.com Advanced Western healthcare systems ‘collapsed’ during Covid-19 pandemic, Russia was better prepared to rapidly mobilize – Putin

The results of Sputnik V’s phase-three trial were confirmed by a review published in The Lancet medical journal earlier this month. The article authored by infectologists from the UK concluded that the trial results show “a consistent strong protective effect across all participant age groups.”

Think your friends would be interested? Share this story!